Jeff Yass’s Avalo Therapeutics AVTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$7.47M Buy
486,975
+459,748
+1,689% +$8.46M ﹤0.01% 3778
2026
Q2
$503K Buy
+27,227
New +$430K ﹤0.01% 9914
2026
Q1
– Sell
-210,994
Closed -$3.3M – 13146
2025
Q4
$3.83M Buy
210,994
+163,596
+345% +$2.76M ﹤0.01% 4471
2025
Q3
$602K Buy
+47,398
New +$408K ﹤0.01% 8541
2023
Q4
– Sell
-95
Closed -$2.74K – 12319
2023
Q3
$2.74K Buy
+95
New +$4.24K ﹤0.01% 11825
2023
Q1
– Sell
-78
Closed -$95K – 12541
2022
Q4
$95K Buy
+78
New +$102K ﹤0.01% 11000
2022
Q2
– Sell
-5
Closed -$11K – 12845
2022
Q1
$11K Sell
5
-4
-44% -$10K ﹤0.01% 12738
2021
Q4
$45K Buy
9
+2
+29% +$12K ﹤0.01% 12601
2021
Q3
$46K Sell
7
-37
-84% -$300K ﹤0.01% 12372
2021
Q2
$412K Buy
44
+16
+57% +$134K ﹤0.01% 10057
2021
Q1
$246K Buy
28
+19
+211% +$180K ﹤0.01% 11013
2020
Q4
$68K Buy
9
+3
+50% +$20.8K ﹤0.01% 10660
2020
Q3
$42K Buy
6
+1
+20% +$7.52K ﹤0.01% 10245
2020
Q2
$39K Hold
5
– – ﹤0.01% 9809
2020
Q1
$36K Buy
+5
New +$52.9K ﹤0.01% 9780
2019
Q4
– Sell
-4
Closed -$35K – 9687
2019
Q3
$35K Buy
+4
New +$44.6K ﹤0.01% 9862
2019
Q2
– Sell
-20
Closed -$329K – 10192
2019
Q1
$329K Buy
+20
New +$299K ﹤0.01% 7057

Other funds holding AVTX

Jeff Yass's AVTX Position: Q3 2026 in Review

Jeff Yass increased its Avalo Therapeutics (AVTX) stake by 1,689% in Q3 2026, buying an estimated $8.46M and bringing the position to 486,975 shares worth $7.47M. The position accounts for ﹤0.01% of the portfolio, ranked #3778.

Jeff Yass first reported a position in AVTX in Q1 2019 and has held it in 17 quarters since. 148 funds tracked by Wall St. Rank hold AVTX as of Q3 2026.

  • Jeff Yass held 486,975 shares of Avalo Therapeutics worth $7.47M as of Q3 2026.
  • Jeff Yass bought 459,748 Avalo Therapeutics shares in Q3 2026, an estimated $8.46M.
  • Avalo Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q3 2026, its #3778 holding.
  • Jeff Yass first reported a position in Avalo Therapeutics in Q1 2019 and has held it in 17 quarters since.
  • 148 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q3 2026.

Based on Susquehanna International Group's 13F filing for Q3 2026, filed 16 Nov 2026.